[Erectile dysfunction and phosphodiesterase type 5 inhibitors].
Copyright policy )[Erectile dysfunction and phosphodiesterase type 5 inhibitors].
Erectile dysfunction affects 150 millions of men and its prevalence increases with age. The improvement of life expectancy will increase the worldwide prevalence to 300 million in 2025. Oral treatments are nowadays the first line therapy for the vast majority of people as they have a good reliability and tolerance and restore more spontaneity. The authors relate the widespread interest in phosphodiesterase type 5 inhibitors with the advent of sildenafil for the treatment of erectile dysfunction and present characteristics of 2 new phosphodiesterase type 5 inhibitors in Belgium, tadalafil and vardenafil.
Cyclic Nucleotide Phosphodiesterases, Type 5, Male, Erectile Dysfunction, 3',5'-Cyclic-GMP Phosphodiesterases, Phosphodiesterase Inhibitors, Phosphoric Diester Hydrolases, Prevalence, Humans, Enzyme Inhibitors
Cyclic Nucleotide Phosphodiesterases, Type 5, Male, Erectile Dysfunction, 3',5'-Cyclic-GMP Phosphodiesterases, Phosphodiesterase Inhibitors, Phosphoric Diester Hydrolases, Prevalence, Humans, Enzyme Inhibitors
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!